PREFER

The patient perspective

PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle. We include patient stakeholders at every level of the project. The end result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

Mats G. Hansson, co-ordinator & Conny Berlin, project leader, PREFER

Finding out what patients prefer

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development.

We are looking forward to sharing our findings with you!

Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader